Rocket Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing allegations of providing misleading information regarding the safety and clinical trial protocol of its RP-A501 treatment, leading to significant stock price decline after the FDA placed a clinical hold on the study due to serious adverse events, including a participant's death [1]. Summary by Sections Allegations - The complaint states that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol [1]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which misled investors into purchasing shares at inflated prices [1]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a serious adverse event, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [1]. Class Action Details - Shareholders who purchased RCKT shares between February 27, 2025, and May 26, 2025, are encouraged to register for the class action lawsuit, with a deadline of August 11, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflate stock prices [3].